Category: News

Post

Aridis Pharmaceuticals, Inc. Presents Positive Phase 2a Safety and Efficacy Data of Salvecin™ (AR-301) in Patients with Severe Pneumonia Caused by Staphylococcus aureus During the 2017 ASM Microbe Congress

2017-06-05 22:37:22/ SAN JOSE, Calif. – June 05, 2017 – Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, presented top-line results of its Phase 2a trial of Salvecin (AR-301), its human monoclonal antibody used as an adjunct therapy for severe pneumonia caused by Staphylococcus aureus,...